HER2 Stratification with a Novel Diagnostic Test

Time: 9:50 am
day: Day One


  • Discovering the potential of the Apis Breast Cancer Subtyping Kit for faster HER2 result turnaround without the need for reflex testing to ISH
  • Learning how to significantly reduce time for results interpretation with automatic results via validated software
  • The detection ability of lowly expressed ERBB2 levels aligns the IVD test as a CDx to HER2 targeted therapies, such as Trastuzumab deruxtecan